12.29
Freenome, Inc. Common stock (FRNM) 最新ニュース
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 - GlobeNewswire Inc.
An updated blood test detected 18.2% of advanced precancerous growths, versus 13.7% in the earlier study. - Stock Titan
IPO Calendar for: - Yahoo! Finance Canada
Freenome, Inc. Common stock (NASDAQ: FRNM) Share Price, FRNM Stock News, FRNM Share Price & Updates - kalkine.ca
Freenome, Inc. Common stock (NASDAQ: FRNM) Share Price, FRNM Stock News, FRNM Share Price & Updates - kalkine.com.au
Roche group holds 18.7M Freenome (NASDAQ: FRNM) shares - Stock Titan
Freenome Registers Up To 75.2 Million Shares For Sale - Yahoo Finance
Jefferies initiates Freenome stock with buy rating on cancer screening potential - Investing.com Nigeria
Freenome, Inc. (FRNM) insider converts 30,000 Class B shares - Stock Titan
Freenome, Inc. (PCSC) director reports common stock and option stakes - Stock Titan
Freenome, Inc. (FRNM) director Douglas Van Oort details equity stake - Stock Titan
Freenome, Inc. (FRNM) CEO details stock and option positions - Stock Titan
Freenome (Nasdaq:FRNM)Stock Analysis - Simply Wall Street
symbol__ Stock Quote Price and Forecast - CNN
Total common shares outstanding of Freenome, Inc. – NASDAQ:FRNM - TradingView
Freenome, Inc. Common stock (FRNM) Historical Quotes - Nasdaq
Form 4 Perceptive Capital Solutions Corp For: 22 July - Investing.com
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch - Wilson Sonsini
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Freenome, Inc. (FRNM) stock price, news, quote and history - Yahoo Finance UK
Freenome (FRNM) Stock Price, News & Analysis - Stock Titan
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection - globenewswire.com
Cancer detection specialist Freenome lists on Nasdaq through special purpose merger - mugglehead.com
Upcoming & Recent IPO'sIPOs Calendar - Yahoo! Finance Canada
Cancer test developer Freenome's SPAC backers seek one-year extension to close deal - The Business Journals
Freenome to go public via PCSC SPAC (PCSC): $240M PIPE, $525M pro forma cash - Stock Titan
Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform - PR Newswire
Cancer detection firm Freenome to go public via $330 million SPAC deal - STAT
PCSC SEC FilingsPerceptive Capital Solutions Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Perceptive Capital Solutions (PCSC) Stock Price, News & Analysis - Stock Titan
AXGN Stock Price and Chart — NASDAQ:AXGN - TradingView
大文字化:
|
ボリューム (24 時間):